Glycominds

Company Overview

Snapshot

Founded in January 1999, Glycominds operated with 11–50 employees. The company was acquired by Medivie Therapeutic in April 2014.

Business overview

Glycominds International is an innovative diagnostics company focused on developing and commercializing gastrointestinal disease management tools and services. The company's core technology involves GI dry serum testing, which helps physicians identify patients with Celiac Disease and Inflammatory Bowel Diseases (Crohn's Disease and Ulcerative Colitis) for early, non-invasive, accurate, and cost-effective diagnosis. Glycominds also provides tools to predict Crohn's Disease patients at higher risk for complicated disease and monitors Anti-TNF therapy. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Medical Diagnostics, and serves the healthcare industry, including laboratories and medical device manufacturers, primarily in the United States.

Company Intelligence Q&A

What was a significant corporate milestone for Glycominds?

Glycominds was acquired by Medivie Therapeutic in April 2014, which expanded its product line.

When did Glycominds go public?

Glycominds succeeded in its TASE IPO in February 2011.

What type of diagnostic tools does Glycominds develop?

Glycominds develops GI dry serum testing tools to identify Celiac Disease and Inflammatory Bowel Diseases, predict disease complications, and monitor Anti-TNF therapy.

In which market does Glycominds primarily operate?

Glycominds primarily operates in the United States market.

What is Glycominds' primary sector?

Glycominds' primary sector is Health Tech & Life Sciences, specifically focusing on Digital Medical Diagnostics.